Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial
- Henry R. Black, MD;
- William J. Elliott, MD, PhD;
- Gregory Grandits, MS;
- Patricia Grambsch, PhD;
- Tracy Lucente, MPH;
- William B. White, MD;
- James D. Neaton, PhD;
- Richard H. Grimm, Jr, MD, PhD;
- Lennart Hansson, MD, PhD;
- Yves Lacourcière, MD;
- James Muller, MD;
- Peter Sleight, MD, DM;
- Michael A. Weber, MD;
- Gordon Williams, MD;
- Janet Wittes, PhD;
- Alberto Zanchetti, MD;
- Robert J. Anders, PharmD;
- for the CONVINCE Research Group
- Author Affiliations: Department of Preventive Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Drs Black and Elliott and Ms
Lucente); Division of Biostatistics (Mr Grandits and Drs Grambsch and Neaton) and Center for Evidence-Based Medicine (Dr Grimm),
University of Minnesota, Minneapolis; Section of Hypertension and Clinical Pharmacology, Department of Medicine, University
of Connecticut School of Medicine, Farmington (Dr White); Department of Geriatrics, University of Uppsala, Uppsala, Sweden
(Dr Hansson); Centre Hospitalier Universitaire de Québec, Québec (Dr Lacourcière); Department of Medicine, Massachusetts General
Hospital, Boston, Mass (Dr Muller); Department of Medicine, Oxford University, and John Radcliffe Hospital, Oxford, England
(Dr Sleight); Department of Medicine, State University of New York, and Brookdale Hospital, Brooklyn (Dr Weber); Brigham and
Women's Hospital and Harvard Medical School, Boston, Mass (Dr Williams); Statistics Collaborative, Washington, DC (Dr Wittes);
Ospedale Maggiore and Istituto Auxologico Italiano and University of Milan, Milan, Italy (Dr Zanchetti); and Clinical Research,
Searle Laboratories, Skokie, Ill (Dr Anders).
Dr Hansson is deceased.
Abstract
Context Hypertensive patients are often given a calcium antagonist to reduce cardiovascular disease risk, but the benefit compared with other drug classes is controversial.
Objective To determine whether initial therapy with controlled-onset extended-release (COER) verapamil is equivalent to a physician's choice of atenolol or hydrochlorothiazide in preventing cardiovascular disease.
Design, Setting, and Participants Double-blind, randomized clinical trial conducted at 661 centers in 15 countries. A total of 16 602 participants diagnosed as having hypertension and who had 1 or more additional risk factors for cardiovascular disease were enrolled between September 1996 and December 1998 and followed up until December 31, 2000. After a mean of 3 years of follow-up, the sponsor closed the study before unblinding the results.
Intervention Initially, 8241 participants received 180 mg of COER verapamil and 8361 received either 50 mg of atenolol or 12.5 mg of hydrochlorothiazide. Other drugs (eg, diuretic, β-blocker, or an angiotensin-converting enzyme inhibitor) could be added in specified sequence if needed.
Main Outcome Measures First occurrence of stroke, myocardial infarction, or cardiovascular disease–related death.
Results Systolic and diastolic blood pressure were reduced by 13.6 mm Hg and 7.8 mm Hg for participants assigned to the COER verapamil group and by 13.5 and 7.1 mm Hg for partcipants assigned to the atenolol or hydrochlorothiazide group. There were 364 primary cardiovascular disease–related events that occurred in the COER verapamil group vs 365 in atenolol or hydrochlorothiazide group (hazard ratio [HR], 1.02; 95% confidence interval [CI], 0.88-1.18; P = .77). For fatal or nonfatal stroke, the HR was 1.15 (95% CI, 0.90-1.48); for fatal or nonfatal myocardial infarction, 0.82 (95% CI, 0.65-1.03); and for cardiovascular disease–related death, 1.09 (95% CI, 0.87-1.37). The HR was 1.05 (95% CI, 0.95-1.16) for any prespecified cardiovascular disease–related event and 1.08 (95% CI, 0.93-1.26) for all-cause mortality. Nonstroke hemorrhage was more common with participants in the COER-verapamil group (n = 118) compared with the atenolol or hydrochlorothiazide group (n = 79) (HR, 1.54 [95% CI, 1.16-2.04]; P = .003). More cardiovascular disease–related events occurred between 6 AM and noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (88/274) groups; HR, 1.15 (95% CI, 0.86-1.53).
Conclusions The CONVINCE trial did not demonstrate equivalence of a COER verapamil–based antihypertensive regimen compared with a regimen beginning with a diuretic or β-blocker. When considered in the context of other trials of calcium antagonists, these data indicate that the effectiveness of calcium-channel therapy in reducing cardiovascular disease is similar but not better than diuretic or β-blocker treatment.
